Vobramitamab duocarmazine, an anti–B7‐H3 antibody–drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion
Cancer · 2026
DOI: 10.1002/cncr.70544 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer, 2026. Verfasst von Eugene Shenderov und 20 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Johns Hopkins Medicine-The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Neoplasms, Indoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Department of Defense Congressionally Directed Medical Research Programs (CDMRP), DOD.
Abstract (Originalsprache)
Background
Vobramitamab duocarmazine is an investigational antibody–drug conjugate (ADC) targeting B7 homolog 3 (B7‐H3) with a cytotoxic duocarmycin‐based DNA‐alkylating payload. This study evaluated its safety and antitumor activity in advanced solid tumors.
Methods
In this phase 1/2 trial (CP‐MGC‐018‐01/NCT03729596), vobramitamab duocarmazine was evaluated at 0.5–4.0 mg/kg intravenously every 3 weeks. The multicohort tumor‐expansion phase focused on metastatic castration‐resistant prostate cancer (mCRPC), lung, breast, melanoma, and squamous head and neck carcinomas. Primary end points were safety and tolerability. Secondary end points included pharmacokinetics, immunogenicity, and antitumor activity.
Results
Across vobramitamab duocarmazine–treated patients, 97.9% (140 of 143) experienced treatment‐related adverse events (TRAEs) of all grades; the grade ≥3 TRAE rate was 65.0% (93 of 143). With two dose‐limiting toxicities in patients receiving 4.0 mg/kg (grade 4 afebrile neutropenia and grade 3 fatigue), the recommended dose for expansion was 3.0 mg/kg. Among all patients treated at 3.0 mg/kg, the rate of grade ≥3 TRAEs was 65.3% (79 of 121) and the confirmed objective response rate (ORR) was 7.2% (seven of 97), with a 6.3‐month median duration of response (DOR). Among patients with mCRPC receiving 3.0 mg/kg, the confirmed ORR was 8.3% (two of 24), with a 5.3‐month median DOR; the confirmed prostate‐specific antigen with a ≥50% decline from the baseline response rate was 43.9% (18 of 41), with a 6.2‐month median DOR.
Conclusions
Vobramitamab duocarmazine demonstrated modest antitumor activity across tumor types, with the most pronounced activity in mCRPC. Treatment was limited by toxicity, particularly pleural effusions and fatigue, which restricted dosing duration. Study treatment was discontinued to refocus on mCRPC in a randomized phase 2 study (TAMARACK/NCT05551117), which was later discontinued after assessment of the vobramitamab duocarmazine safety and efficacy profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Johns Hopkins Medicine-The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
- The START Center for Cancer Research-Midwest, Grand Rapids, Michigan, USA.
- Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
- Carolina BioOncology Institute, Huntersville, North Carolina, USA.
- Centre of Excellence in Precision Cancer Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Research Institute, Virginia Cancer Specialists, Fairfax, Virginia, USA.
ORCID-Profile: Eugene Shenderov, Emiliano Calvo
Förderung
- NCI NIH HHS
- Department of Defense Congressionally Directed Medical Research Programs (CDMRP)
- DOD
- MacroGenics, Inc
- NIH/NCI
- Prostate Cancer Foundation
Zitieren
APA
Shenderov, E., Sharma, M. R., Garralda, E., Powderly, J., Ługowska, I., Spira, A., Salamero, M. C., Jang, S., Cosman, R., Shen, J., Xu, W., Wysocki, P. J., Ramlau, R., Antonarakis, E. S., Weickhardt, A. J., Żołnierek, J., Calvo, E., Zhao, E., Bohac, C., …, & Mallesara, G. (2026). Vobramitamab duocarmazine, an anti–B7‐H3 antibody–drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion. Cancer. https://doi.org/10.1002/cncr.70544
Vancouver
Shenderov E, Sharma MR, Garralda E, Powderly J, Ługowska I, Spira A, et al. Vobramitamab duocarmazine, an anti–B7‐H3 antibody–drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion. Cancer. 2026. doi:10.1002/cncr.70544
BibTeX
@article{Shenderov2026,
author = {Shenderov, Eugene and Sharma, Manish R and Garralda, Elena and Powderly, John and Ługowska, Iwona and Spira, Alexander and Salamero, Marc Cucurull and Jang, Sekwon and Cosman, Rasha and Shen, John and Xu, Wen and Wysocki, Piotr J and Ramlau, Rodryg and Antonarakis, Emmanuel S and Weickhardt, Andrew J and Żołnierek, Jakub and Calvo, Emiliano and Zhao, Enxu and Bohac, Chet and Ward, Ashley and Mallesara, Girish},
title = {Vobramitamab duocarmazine, an anti–B7‐H3 antibody–drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70544}
}
EUVIMED